Program 2024 (click to view)

Program 2023 (click to view)

Program 2022 (click to view)

 

Program 2019

 

Wednesday September 25
09.00-10.00 Registration
  Opening Session (Nina Weis)
10.15-10.20 Welcome (Magnus Gisslén)
10.20-10.50 Opening Plenary (Pl1)
Co-morbidities in treated HIV infection (Susanne Dam Poulsen, Denmark)
10.50-11.00 Discussion
  Abstract Session I (Jan Gerstoft & Magnus Gottfredsson)
11.00-11.15 Oral 1 (10 min + 5 min discussion)
Antiretroviral treatment initiated at high CD4 cell counts does not normalize cerebrospinal fluid markers of immune activation
Frida Rydberg
11.15-11.30 Oral 2
Employment of people living with HIV approaching that of the HIV-negative population irrespective of migrant status and sexual orientation
Christina Carlander
11.30-11.45 Oral 3
The burden of comorbidities in people living with HIV (PLHIV) in Central Denmark Region
Niels A. Jespersen
11.45-12.00 Oral 4
Activated and exhausted CD8 T-cells differentiate aviremic HIV-2 infected from seronegative individuals
Lydia Scharf
12.00-13.00 Lunch
13.00-13.50 BHIVA and HIV Nordic joint session – Evolving HIV treatment and care (Nina Weis & Chloe Orkin)
  New drugs and treatment strategies (Chloe Orkin, UK)
  Cervical cancer and dysplasia in HIV (Christina Carlander, Sweden)
  Discussion
  Plenary session I – HIV treatment and clinical challenges (Leo Flamholc & Veronica Svedhem Johansson)
13.50-14.15 Plenary (Pl2)
INSTI adverse events – what is the truth? (Jan Gerstoft, Denmark)
14.15-14.25 Discussion
14.25-14.40 Short Break
14.40-15.10 Plenary (Pl3)
Update on ART and birth defects (Claudia Crowell, USA)
15.10-15.20 Discussion
15.20-15.50 Plenary (Pl4)
Resurgent STIs in HIV Care and Prevention (Sharon Walmsley, Canada)
15.50-16.00 Discussion
16.00-16.30 Coffee and exhibition/posters
16.30-17.30 Satellite Symposium 1 – MSD
The role of NNRTI in modern ART
Want to join online?: See program & register for webcast here!
Moderator/Lecturer: Prof Magnus Gisslén, Sahlgrenska Universitetssjukhuset/Östra (Sweden)
Lecturer: Dr Emmi Andersson, Karolinska University (Sweden)
17.30-17.45 Short break
17.45-18.45 Satellite Symposium 2 – Gilead HIV
Presenting late with HIV in the Nordics: What can we do better to reduce disease and transmission burden?
An interactive session with panel discussion and questions for the audience.
Moderator: Ole Kirk, Rigshospitalet (Denmark)
Panel: Anders Sönnerborg, Karolinska Institutet (Sweden),
Pia Kivelä, Helsinki University Hospital (Finland),
Magnús Gottfreðsson, National University Hospital of Iceland
18.45- Poster Exhibition with cheese and snacks
   

 

Thursday September 26
08.00-09.00 Satellite Symposium 3 – GSK/ViiV
Why use 3 when 2 could be enough?
Moderator: Prof Magnus Gisslén
Two drug regimens (2DRs) in the Nordic countries, experience and guidelines (Prof Magnus Gisslén, Sweden)
Treatment with less drugs – Why? How? When? (Prof Chloe Orkin UK)
09.00-09.10 Short break
  Plenary Session II – Reservoirs and Cure (Magnus Gisslén & Francesca Chiodi)
09.10-09.40 Plenary (Pl5)
New insights in formation of the HIV reservoir (Ron Swanstrom, USA)
09.40-09.50 Discussion
09.50-10.20 Plenary (Pl6)
Viral reservoirs in tissue (Jacob Estes, USA)
10.20-10.30 Discussion
10.30-11.00 Coffee and Poster exhibition
  Plenary Session III – HIV control (Anders Sönnerborg & Helene Mens)
11.00-11.30 Plenary (Pl7)
Functional Cure of HIV (Lucy Dorrell, Oxford, UK)
11.30-11.40 Discussion
11.40-12.10 Plenary (Pl8)
Mechanisms of elite control (Beatriz Mothe, Spain)
12.10-12.20 Discussion
12.20-12.50 Plenary (Pl9)
Mechanisms of post-treatment control (John Frater, UK)
12.50-13.00 Discussion
13.00-14.00 Lunch
  Plenary Session IV – Last year’s most important achievements in the HIV research field (Jussi Sutinen & Annika Karlsson)
14.00-14.30 Plenary (Pl10)
Top 5 in basic HIV research 2018-2019 (Marianne Jansson, Sweden)
14.30-15.00 Plenary (Pl11)
Top 5 in clinical HIV research 2018-2019 (Terese Katzenstein, Denmark)
  Plenary Session V – Virology (Dan Henrik Reikvam & Aylin Yilmaz)
15.00-15.20 Plenary (Pl12)
Update on INSTI resistance (Anne-Geneviève Marcelin, France)
15.20-15.30 Discussion
15.30-15.50 Plenary (Pl13)
Significance of low-level viremia during antiretroviral treatment (Anders Sönnerborg, Sweden)
15.50-16.00 Discussion
16.00-16.20 Coffee and Poster exhibition
16.20-16.30 HIV & Hepatitis Nordic Conference 2019 Abstract Award (Leo Flamholc)
16.30-17.30 Satellite Symposium 4 – Gilead HCVtreatment at opioid substitution therapy clinics
Want to join online?: See program & register for webcast here!
Moderator: Martin Kåberg, MD, PhD, Medical Supervisor, Stockholm Needle Exchange, Stockholm Centre for Dependency Disorders
Lecturers: Per-Erik Klasa, Senior consultant Psychiatry/Addiction medicine, LARO Prima Maria,
Tove Lindholm, HCV responsible nurse, LARO-mottagningen, Akademiska Sjukhuset
19.00 Conference Dinner
   

 

Friday September 27
  Plenary Session VI – Last year’s most important achievements in the hepatitis field (Soo Aleman)
09.00-09.30 Plenary (Pl14)
Top 5 in hepatitis research 2017/18 (Ola Weiland, Sweden)
09.30-09.40 Discussion
  Abstract Session II (Nina Weis)
09.40-09.55 Oral 5 (10 + 5 min discussion)
A long-term study of 337 hepatitis D virus (HDV) and hepatitis B virus co-infected patients: the impact of HDV viremia on liver-related outcomes
Habiba Kamal
09.55-10.10 Oral 6
4 week treatment for hepatitis C – a randomized controlled trial (4RIBC)
Lone Wulff Madsen
10.10-10.45 Coffee and Poster exhibition
  Session VII – HCV treatment among people who inject drugs – experiences from Norway, Denmark and Sweden
(Martin Kåberg, Sweden & Marianne Alanko, Sweden)
10.45-12.15 Olav Dalgard (Norway)
Anne Øvrehus (Denmark)
Anna Jerkeman (Sweden)
12.15-13.15 Lunch
  Plenary Session VIII – Hepatitis B/D (Magnus Lindh & Dan Henrik Reikvam)
13.15-13.35 Plenary 15
Immunological aspects of stopping NUC treatment in HBV (Niklas Björkström, Sweden)
13.35-13.45 Discussion
13.45-14.05 Plenary 16
Future options for treatment of hepatitis delta (Maria Buti, Spain)
14.05-14.15 Discussion
14.15-14.35 Plenary 17
Hepatitis B cure – progress, obstacles and definitions
(Johannes Vermehren, Germany)
14.35-14.45 Discussion
14.45-15.00 Short break
  Plenary Session IX – Hepatitis C (Soo Aleman & Ola Weiland)
15.00-15.20 Plenary 18
Aspects on HCV vaccine development (Jannick Prentø, Denmark)
15.20-15.30 Discussion
15.30-15.50 Plenary 19
Eradicating HCV, a global perspective (John Dillon, UK)
15.50-16.00 Discussion
16.00-16.15 Concluding remarks (Nina Weis)
   

 

Program 2018

 

Wednesday September 26
 
09.00-10.00 Registration
  Opening session
Moderators: Magnus Gisslén & Nina Weis
10.15-10.20 Welcome (Nina Weis, Denmark)
10.20-10.50 Opening Plenary 1
Progress towards reaching the 90-90-90 HIV target in Europe and beyond (Anastasia Pharris, ECDC, Sweden)
10.50-11.00 Discussion
  Abstract Session I
Moderators: Magnus Gisslén & Nina Weis
11.00-11.15 Oral 1 (10 min + 5 min discussion)
HPV genotypes identified in migrant women living with HIV are not covered for by current HPV vaccines; results from an interim analysis
Christina Carlander
11.15-11.30 Oral 2
Frequency of co-expression of inhibitory receptors early in HIV infection determines progression rate in untreated patients.
Lydia Scharf
11.30-11.45 Oral 3
Switching to FTC/TAF from either ABC/3TC or FTC/TDF does not affect central nervous system HIV-1 infection
Aylin Yilmaz
11.45-12.00 Oral 4
Gut mucosal CD4 T cells of immunological non-responders with low CD4/CD8 ratio have increased cytokine production, which may be reduced by probiotics
Malin H Meyer-Myklestad
12.00-13.00 Lunch
  Plenary Session I
Moderators: Matti Ristola & Magnus Gottfredsson
13.00-13.30 Plenary 2
Mortality and morbidity among children and adolescents with perinatal HIV infection (Ruth Goodall, UK)
13.30-13.40 Discussion
13.40-14.10 Plenary 3
HIV infected women and breastfeeding (Ellen Moseholm Larsen, Denmark)
14.10-14.20 Discussion
14.20-14.35 Short break
14.35-15.50 BHIVA and HIV Nordic joint session – Aspects on HIV prevention in high-risk-populations
Moderators: Magnus Gisslén & Caroline Sabin
Speakers: Chemsex (Ann Sullivan, UK)
PrEP, implementation in Norway (Frank Olav Pettersen, Norway)
Declining HIV prevalence among MSM in London (Ann Sullivan, UK)
Discussion
15.50-16.30 Coffee and exhibition/posters
16.30-17.30 Satellite Symposium I (Janssen)
What you need to know about HIV and bone – a medical education event
Moderator: Lars Østergaard, Skejby, Aarhus, Denmark
Speakers: Mas Chaponda, Royal Liverpool University Hospital, Liverpool, UK, Steffen Leth, Skejby, Aarhus, Denmark, Jon Wetterberg, Venhälsan, Södersjukhuset i Stockholm
17.30-17.45 Short break
17.45-18.45 Satellite Symposium II (GSK/ViiV)
Can less be more? Let 2-morrow start 2-day
Moderator: Eva Fernvik, Sr Scientific Advisor HIV, GSK/ViiV Healthcare
Why use a two drug regimen (2DR)?
– Tia Vincent, PhD, Director Global Scientific Affairs, ViiV Healthcare
The hiv-patient and stigma – the biggest hurdle for a life with high quality?
– Maria Lindberg Reinius, RN, PhD, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet
18.45- Poster Exhibition with cheese and snacks
   

 

Thursday September 27
08.00-09.00 Satellite Symposium III – HIV Outcome
Stigma inom hälsovårdssystemet – behövs en certifiering?
The lecture and concluding panel discussion will take place in Swedish.
Speakers: Anders Sönnerborg, Karolinska Institutet, Lars E. Eriksson, Karolinska Institutet, Peter Månehall, HIV-Sverige & a group of panelist for a concluding discussion.
09.00-09.10 Short break
  Plenary Session II – Inflammation and reservoirs
Moderators: Anders Sönnerborg & Annika Karlsson
09.10-09.40 Plenary 6
Tissue resident T-cells and immunity during acute and chronic HIV-infection (Mike Betts, USA)
09.40-09.50 Discussion
09.50-10.20 Plenary 7
Microbial translocation and microbiome dysbiosis in HIV-associated immune activation (Piotr Nowak, Sweden)
10.20-10.30 Discussion
10.30-11.00 Coffee and exhibition/posters
11.00-11.30 Plenary 8
Is it possible to enhance immune function in HIV-infected persons on ART with immune failure? (Michael Lederman, USA)
11.30-11.40 Discussion
  Plenary Session III – Living with HIV
Moderators: DH Reikvam & Aylin Yilmaz
11.40-12.10 Plenary 9
Life expectancy and long-term outlook in PLHIV (Caroline Sabin, UK)
12.10-12.20 Discussion
12.20-12.50 Plenary 10
Recent achievements in Next-Generation Sequencing (NGS) of HIV and possible clinical implications (Roger Paredes, Spain)
12.50-13.00 Discussion
13.00-14.00 Lunch
  Plenary Session IV – Last year’s most important achievements in the HIV research field
Moderators: Francesca Chiodi & Jan Gerstoft
14.00-14.30 Plenary 11
Top 5 in basic HIV research 2017-2018 (Jan Albert, Sweden)
14.30-14.40 Discussion
14.40-15.10 Plenary 12
Top 5 in clinical HIV research 2017-2018 (Anne-Mette Kjær Lebech, Denmark)
15.10-15.20 Discussion
15.20-15.40 Plenary 13
The history of HIV in Finland (Matti Ristola, Finland)
15.40-15.45 HIV & Hepatitis Nordic Conference 2018 Abstract Award
(Matti Ristola, Finland)
15.45-16.15 Coffee and exhibition/posters
16.15-17.15 Satellite Symposium IV (Gilead HIV)
What is the role of the new integrase inhibitor in the management of HIV patients?
Moderator: Leo Flamholc, Department of infectious diseases, Malmö University hospital
Lecturer: Joel Gallant, Sr. Director of Medical Affairs, Gilead Scienses Inc, USA
  Conference dinner
   

 

Friday September 28
08.00-09.00 Satellite Symposium V (Gilead HCV)
Elimination of HCV – experience from Iceland
Moderator: Soo Aleman MD, PhD, assoc prof, head of HIV, viral hepatitis and immunodeficiency units at Department of Infectious Diseases, Karolinska University Hospital
Lecturer: Valgerður Rúnarsdóttir, Medical Director, Vogur University Hospital
Sigurdur Olafsson, Director of Hepatology, Landspitali University Hospital
Magnus Gottfredsson, MD, PhD, Landspitali University Hospital
  Plenary Session V – Last year’s most important achievements in the hepatitis field
Moderators: Ola Weiland & Helene Mens
09.10-09.40 Plenary 14
Top 5 in hepatitis research 2017/18 (Martti Färkkilä, Finland)
09.40-09.50 Discussion
  Abstract Session II
Moderators: Ola Weiland & Helene Mens
09.50-10.05 Oral 5 (10 + 5 min discussion)
Acute Hepatitis E Virus Genotype 3 Infection Associated with Acute Pancreatitis
Miriam Karlsson
10.05-10.20 Oral 6
Enhancing the hepatitis C (HCV) care cascade for people who inject drugs (pwid) at the Stockholm needle exchange
Martin Kåberg
10.20-11.00 Coffee and exhibition/posters
  Plenary Session VI
Moderators: Magnus Lindh & Nina Weiss
11.00-11.30 Plenary 15
Update on hepatitis E (Heléne Norder, Sweden)
11.30-11.40 Discussion
11.40-12.10 Plenary 16
Can HCC surveillance be stopped?/ Post SVR surveillance (Sofie Hallager, Denmark)
12.10-12.20 Discussion
12.20-13.20 Lunch
  Plenary Session VII
Moderators: Leo Flamholc & Ola Weiland
13.20-13.50 Plenary 17
HCV treatment in needle exchange programs (Marianne Alanko, Sweden)
13.50-14.00 Discussion
14.00-14.30 Plenary 18
HCV treatment in the prison systems (Soo Aleman, Sweden)
14.30-14.40 Discussion
14.40-15.10 Plenary 19
Global Perspectives on HCV Eradication (Jeff Lazarus, UK)
15.10-15.20 Discussion
15.20-15.30 Concluding remarks
Moderator: Magnus Gisslén
   

 

Program 2017

 

Wednesday September 27
 
09.00-10.00 Registration
  Opening session
(Magnus Gisslén, Sweden, Nina Weis, Denmark)
10.15-10.20 Welcome (Magnus Gisslén, Sweden and Nina Weis, Denmark)
10.20-10.50 Opening Plenary 1
Persistent immunological problems in the ART era (Francesca Chiodi, Sweden)
10.50-11.00 Discussion
  Plenary Session I – Immune reconstitution inflammatory syndrome (IRIS)
(Veronica Svedhem Johansson, Sweden, Matti Ristola, Finland)
11.00-11.25 Plenary 2
Pathogenic and clinical aspects on IRIS in HIV (Irini Sereti, USA)
11.25-11.35 Discussion
11.35-12.00 Plenary 3
Integrase inhibitors and the risk of IRIS (Bart Rijnders, The Netherlands)
12.00-12.10 Discussion
12.10-13.10 Lunch
  Plenary Session II – ART
(Anders Sönnerborg, Sweden, Magnus Gisslén, Sweden)
13.10-13.35 Plenary 4
Injectable drugs and other long-acting agents against HIV (Jan Gerstoft, Denmark)
13.35-13.45 Discussion
13.45-14.10 Plenary 5
Is HIV management moving towards personalized medicine? (Carlo-Federico Perno, Italy)
14.10-14.20 Discussion
14.20-14.45 Plenary 6
Clinical use of HIV DNA quantification and genotyping.
(Maurizio Zazzi, Italy)
14.45-14.55 Discussion
14.55-15.20 Plenary 7
The threat of increasing HIV drug resistance and the need for global action (Silvia Bertagnolio, Switzerland)
15.20-15.30 Discussion
15.30-15.45 Short break
  Abstract Session I
(Annika Karlsson, Sweden, Leo Flamholc, Sweden)
15.45-16.00 Oral 1 (10 min + 5 min discussion)
CSF Anti-HIV Antibody Decline by Early Antiretroviral Therapy Suggests Reduced HIV Persistence in the CNS. (Magnus Gisslén, Sweden)
16.00-16.15 Oral 2
Suppressive antiretroviral therapy is associated with effective treatment of high-grade cervical intraepithelial neoplasia. (Christina Carlander, Sweden)
16.15.16.30 Oral 3
Decreasing HIV-1 incidence and undiagnosed HIV-1 cases in Sweden based on multiple biomarker estimate of infection times. (Jan Albert, Sweden)
16.30-16.45 Oral 4
Genome wide association studies to characterize the HIV-1 positive Elite Controller (EC) cohort in Sweden. (Sara Svensson Akusjärvi, Sweden)
16.45-17.15 Coffee and exhibition/posters
17.15-18.15 Satellite Symposium I – GSK/ViiV
Dolutegravir – from development to real-life safety and universal access (Annemiek de Ruiter, Senior Global Medical Director, ViiV Healthcare and Eva Fernvik, PhD, Senior Scientific Advisor GSK/ ViiV Healthcare)
18.15-18.25 Short break
18.25-19.25 Satellite Symposium II – Janssen (HIV)
CNS Complications in HIV Patients
(Lars Østergaard/Steffen Leth Denmark, Aylin Yilmaz/Erika Ahlgren Sweden, Paola Cinque, Italy)
19.25- Poster Exhibition with cheese and snacks
   
   

 

Thursday September 28
08.00-09.00 Satellite Symposium III – Gilead
HIV and Women (Christina Carlander, moderator, & Teresa Katzenstein)
09.00-09.10 Short break
  Plenary Session III – Last year’s most important achievements in the HIV research field
(Francesca Chiodi, Sweden Anders Blaxhult, Sweden)
09.10-09.40 Plenary 8
Top 5 in basic HIV research 2016/17 (Johan Sandberg, Sweden)
09.40-09.50 Discussion
09.50-10.20 Plenary 9
Top 5 in clinical HIV research 2016/17 (Aylin Yilmaz, Sweden)
10.20-10.30 Discussion
10.30-11.00 Coffee and exhibition/posters
  Plenary Session IV – Reservoirs and cure
(Helene Mens, Denmark, Magnús Gottfreðsson, Iceland)
11.00-11.30 Plenary 10
Functional cure by integrin antibody therapy? (Aftab Ansari, USA)
11.30-11.40 Discussion
11.40-12.10 Plenary 11
“Soothe and snooze” as an alternative to “kick and kill” (Susana Valente, USA)
12.10-12.20 Discussion
12.20-12.50 Plenary 12
Stem cell transplantations – status post-the Berliner and Boston-patients (Javier Martinez-Picado, Spain)
12.50-13.00 Discussion
13.00-14.00 Lunch
  Plenary Session V – Complications, co-morbidities etc.
(Jan Gerstoft, Denmark, Magnus Gisslén, Sweden)
14.00-14.30 Plenary 13
Protease inhibitors and risk of cardio-/cerebro-vascular disease (Ann-Brit Eg Hansen, Denmark)
14.30-14.40 Discussion
14.40-15.10 Plenary 14
Symptomatic CNS escape including CD8-encephalitis during cART (Paola Cinque, Italy)
15.10-15.20 Discussion
15.20-15.30 HIV & Hepatitis Nordic Conference 2017 Abstract Award
(Anders Sönnerborg/Sophie Ekman, Sweden)
15.30-16.00 Coffee and exhibition/posters
16.00-17.00 Satellite Symposium IV – Abbvie (HCV)
The era of pan-genotypic next generation HCV treatment
(Jean-Michel Pawlotsky, France)
17.00-17.10 Short break
17.10-18.10 Satellite Symposium V – Gilead
Många personer som injicerar droger står utan hepatit C‐vård.
• Hur kan vi i Sverige ge optimal hjälp?
En paneldebatt modererad av Barbro Westerholm, riksdagsledamot Liberalerna.
Deltagare: Fred Nyberg, Professor, U-Fold, Uppsala Universitet, Martin Kåberg, medicinskt ansvarig sprutbytet Stockholm, Marianne Alanko Blomé, medicinskt ansvarig sprutbytet Malmö, Anders Nystedt, Smittskyddsläkare, Luleå, Lars-Håkan Nilsson, Medicinskt ansvarig Kriminalvården
Aprx. 19.30 Conference dinner
   

 

Friday September 29
08.00-09.00 Satellite Symposium VI – MSD (HCV)
Towards HCV-Elimination in the Nordics (Olav Dalgard, Hannah Fraser, Martin Kåberg, Lars Peters, Knut Bo Kieland, Henrikki Brummer-Korvenkontio)
  Plenary Session VI – Last year’s most important achievements in the hepatitis field
(Ola Weiland, Sweden)
09.10-09.40 Plenary 15
Top 5 in hepatitis research 2016/17 (Soo Aleman, Sweden)
09.40-09.50 Discussion
  Abstract Session II
(Martti Färkkilä, Finland Olav Dalgard, Norway)
09.50-10.05 Oral 5 (10 + 5 min discussion)
High BMI, pre-treatment cirrhosis and older age increase the risk for persisting advanced fibrosis after SVR in patients with chronic HCV. (Magnus Hedenstierna, Sweden)
10.05-10.20 Oral 6
Increased NK cell function after cessation of long-term NUC treatment in chronic hepatitis B associates with liver damage and HBsAg loss. (Niklas K. Björkström, Sweden)
10.20-11.00 Coffee and exhibition/posters
  Plenary Session VII – Hepatitis B
(Nina Weis, Denmark, Leo Flamholc, Sweden)
11.00-11.30 Plenary 16
Immunopathology and immunotherapy in HBV (Mala Maini, UK)
11.30-11.40 Discussion
11.40-12.10 Plenary 17
Are HBV DNA integrations relevant, and is HBV RNA a useful clinical marker? (Magnus Lindh, Sweden)
12.10-12.20 Discussion
12.20-13.20 Lunch
  Plenary Session VIII – Hepatitis C
(Soo Aleman, Sweden, Matti Sällberg, Sweden)
13.20-13.50 Plenary 18
Pangenotypic and shorter treatment (Christophe Hézode, France)
13.50-14.00 Discussion
14.00-14.30 Plenary 19
Immunomodulation during DAA treatment and the clinical impact (Robert Thimme, Germany)
14.30-14.40 Discussion
14.40-15.10 Plenary 20
HCV vaccines – an overview (Judith Gottwein, Denmark)
15.10-15.20 Discussion
15.20-15.30 Concluding remarks
   

 

Program 2016

 

Wednesday September 28
  Opening session
10.15-10.20 Welcome (Magnus Gisslén, Sweden)
10.20-11.00 Opening Plenary 1
The most important achievements from the Copenhagen HIV Programme (CHIP) (Jens Lundgren, Denmark)
11.00-11.10 Discussion
  Plenary session I – HIV co-morbidities
(Magnús Gottfreðsson, Iceland and Aylin Yilmaz, Sweden)
11.10-11.40 Plenary 2
HIV and stroke (Laura Benjamin, UK)
11.40-11.50 Discussion
11.50-12.20 Plenary 3
HIV and osteoporosis (Paddy Mallon, Ireland)
12.20-12.30 Discussion
12.30-13.30 Lunch
   
  Plenary session II – HIV, aspects on epidemiology
(Anders Blaxhult, Sweden and Arild Maeland, Norway)
13.30-14.00 Plenary 4
The early spread of HIV in human populations and the role of iatrogenic transmission (Oliver Pybus, UK)
14.00-14.10 Discussion
14.10-14.40 Plenary 5
PrEP: moving from clinical trials to routine practice? (Richard Gilson, UK)
14.40-14.50 Discussion
14.50-15.00 Short break
  Abstract Session I
(Jan Gerstoft, Denmark and Veronica Svedhem Johansson, Sweden)
15.00-15.20 Oral 1 (Discussion included)
O1-16. Near full-length HIV-1 genome sequencing reveals higher intra-country spread of unique recombinant forms (URFs) among patients infected in Sweden (Ujjwal Neogi, Sweden)
15.20-15.40 Oral 2
O2-16. HIV-testing women with cervical dysplasia (Christina Carlander, Sweden)
15.40-16.00 Oral 3
O3-16. Structural Basis of Inhibition and Resistance Mechanism to EFdA, a highly potent NRTI (Stefan G. Sarafianos, USA)
16.00-16.30 Coffee and exhibition/posters
16.30-17.30 Satellite Symposium I – Janssen
Individualized ART 2016; pros and cons of guideline preferred regimens
Representing bPI – Chloe Orkin (UK), Representing NNRTI – Magnus Gisslén (SE), Representing INI – Jan Gerstoft (DK)
Moderator – Anton Pozniak, UK
17.30-17.45 Short break
17.45-18.45 Satellite Symposium II – Gilead
TAF – A In Depth Review (Cal Cohen, USA)
18.45-20.00 Poster Exhibition with cheese and snacks
   

 

Thursday September 29
08.00-09.00 Satellite Symposium III – GSK/ViiV
Building the HIV-treatment around the core agent. Why? Why not!
At the Core: A new era of ART?!
Women living with HIV: Specific needs?
ARIA: New data on women on ART
Questions & Closing remarks
  Plenary Session III – Last year’s most important achievements in the HIV research field
(Magnus Gisslén, Sweden and Helene Mens, Denmark)
09.10-09.40 Plenary 6
Top 5 in basic HIV research 2015/16 (Annika Karlsson, Sweden)
09.40-09.50 Discussion
09.50-10.20 Plenary 7
Top 5 in clinical HIV research 2015/16 (Magnús Gottfreðsson, Iceland)
10.20-10.30 Discussion
10.30-11.00 Coffee and Poster exhibition
   
  Plenary Session IV – ART in low- and middle-income countries
(Matti Ristola, Finland and Anders Sönnerborg, Sweden)
11.00-11.30 Plenary 8
ART-resistance emergence in low- and middle-income countries (Ravindra Gupta, UK)
11.30-11.40 Discussion
11.40-12.10 Plenary 9
Future development of HIV treatment in Africa (Andrea de Luca, Italy)
12.10-12.20 Discussion
12.20-13.30 Lunch
   
  Plenary Session V – HIV persistence and reservoirs
(Francesca Chiodi, Sweden and Annika Karlsson, Sweden)
13.30-13.50 Plenary 10
T-cell exhaustion in HIV (Marcus Buggert, USA)
13.50-14.00 Discussion
14.00-14.30 Plenary 11
Persistent HIV-1-replication in lymphoid tissues (Steven Wolinsky, USA)
14.30-14.40 Discussion
14.40-15.10 Plenary 12
Gene therapy for HIV cure (Paula M Cannon, USA)
15.10-15.20 Discussion
15.20-15.30 HIV & Hepatitis Nordic Conference 2016 Poster Award
(Gunnar Norkrans, Sweden)
15.30-16.00 Coffee and exhibition/posters
16.00-17.00 Satellite Symposium IV – Abbvie
Real World Evidence in HCV-challenges. (Prof. Dr. med. Stefan Zeuzem)
17.00-17.10 Short break
17.10-18.10 Satellite Symposium V – BMS
HCV-real world and InCare data (Ola Weiland, Sweden)
18.10-18.20 Short break
18.20-19.20 Satellite Symposium VI – MSD
HCV Treatment and the Incarcerated Population: Canadian & Nordic Approaches Today & Tomorrow (Stephen D. Shafran, Canada, Anders Nystedt, Sweden, Kaarlo Simojoki, Finland) Moderator – Dr. Soo Aleman, Sweden
  Dinner
   

 

Friday September 30
08.00-09.00 Satellite Symposium VII – Gilead
Pan genotypic treatment of hepatitis C – new possibilities. Elimination on the horizon? (Thomas Berg, Germany)
The Portuguese experience – implementation of national plan for elimination of hepatitis C (Rui Tato Marinho, Portugal)
   
  Plenary Session VI – Treatment of hepatitis B and D
(Magnus Lindh, Sweden and Matti Sällberg, Sweden)
09.10-09.40 Plenary 13
HBV: Future treatment approaches (Thomas Berg, Germany)
09.40-09.50 Discussion
09.50-10.20 Plenary 14
HDV: Future treatment approaches (Markus Cornberg, Germany)
10.20-10.30 Discussion
10.30-11.15 Coffee and Poster exhibition
   
  Abstract Session II
(Soo Aleman, Sweden and Olav Dalgard, Norway)
11.15-11.35 Oral 4 (Discussion included)
O4-16. Hepatocellular carcinoma among patients with chronic hepatitis C and cirrhosis in Denmark (Sofie Hallager, Denmark)
11.35-11.55 Oral 5
O5-16. TRAP HEP C – Treatment as Prevention for Hepatitis C in Iceland. A nationwide elimination program using direct acting antiviral agents (Magnus Gottfredsson, Iceland)
   
  Plenary Session VII – SVR in HCV, impact on complications and co-morbidities
(Ola Weiland, Sweden and Nina Weiss, Denmark)
12.00-12.30 Plenary 15
The risks for hepatocellular carcinoma after cure of HCV in eras of interferon and direct acting antivirals (Soo Aleman, Sweden)
12.30-12.40 Discussion
12.40-13.10 Plenary 16
Impact of diabetes mellitus on long term risk of HCC after SVR (Magnus Hedenstierna, Sweden)
13.10-13.20 Discussion
   
13.20-14.20 Lunch
   
  Plenary Session VIII – Last year’s most important achievements in the hepatitis field and aspects on treatment of HCV
(Leo Flamholc, Sweden and Ola Weiland, Sweden)
14.20-14.50 Plenary 17
Top 5 in hepatitis research (Nina Weis, Denmark)
14.50-15.00 Discussion
15.00-15.30 Plenary 18
HCV resistance, impact on treatment choice? (Christoph Sarrazin, Germany)
15.30-15.40 Discussion
15.40-16.10 Plenary 19
Treatment of PWIDs, opioid substitution, and the risk of reinfection (Olav Dalgard, Norway)
16.10-16.20 Discussion
16.20-16.30 Concluding remarks
(Anders Sönnerborg, Sweden)
   

 

Program 2015

 

Wednesday September 30
  Opening session
10.45-11.00 Welcome (Magnus Gisslén)
11.00-11.45 Opening Plenary 1
35 years of HIV research – problems solved and challenges that remain (Jan Gerstoft, Denmark)
11.45-12.00 Discussion
12.00-13.00 Lunch
   
  Plenary session I – The HIV pandemic (Annika Karlsson and Anders Blaxhult)
13.00-13.30 Plenary 2
The impact of HIV adaptation on virulence (Philip Goulder, UK)
13.30-13.40 Discussion
13.40-14.10 Plenary 3
Update on the HIV epidemic in Russia (Vadim Pokrovskiy, Russia)
14.10-14.20 Discussion
   
  Plenary Session II – T-cells (Francesca Chiodi and Helene Mens)
14.20-14.50 Plenary 4
CD4 T-cell depletion in HIV-1 infection (Warner Greene, USA)
14.50-15.00 Discussion
15.00-15.30 Plenary 5
The CD4/CD8 ratio as a predictor of T cell activation in treated and untreated HIV infection (Annika Karlsson, Sweden)
15.30-15.40 Discussion
15.40-16.00 Coffee and exhibition/posters
   
16.00-17.00 Satellite Symposium I – Gilead
Inflammation and Immune Activation in HIV (Allison Ross Eckard, USA)
Moderator: Anders Sönnerborg, Sweden
17.00-17.10 Short break
17.10-18.10 Satellite Symposium II – Janssen
The evolution of modern HIV treatment – factors that influence and what it means in clinical practice (Anton Pozniak, UK and Magnus Gisslén, Sweden)
Moderator: Stefan Lindbäck, Janssen
   
   

 

Thursday October 1
08.00-09.00 Satellite Symposium III – GSK/ViiV
What’s next to know about Dolutegravir? Partnerships? And the Patient? (Els Hollanders, Belgium, Anna Lawson, UK, Ophelia Haanyama, Sweden)
Moderator: Eva Fernvik, Sweden
  Plenary Session III – Last year’s most important achievements in the HIV research field (Anne Ma Dyrholt and Matti Ristola)
09.10-09.40 Plenary 6
Top 5 in basic HIV research 2014/15 (Helene Mens, Denmark)
09.40-09.50 Discussion
09.50-10.20 Plenary 7
Top 5 in clinical HIV research 2014/15 (Arild Maeland, Norway)
10.20-10.30 Discussion
10.30-11.00 Coffee and Poster exhibition
   
  Plenary Session IV – Latency and cure / Inflammation and ageing (Magnus Gisslén and Anders Sönnerborg)
11.00-11.30 Plenary 8
Reversing HIV latency (Robert Siliciano, USA)
11.30-11.40 Discussion
11.40-12.10 Plenary 9
Mitigation of inflammation in HIV-infection (Steve Deeks, USA)
12.10-12.20 Discussion
12.20-12.50 Plenary 10
HIV and ageing (Giovanni Guaraldi, Italy)
12.50-13.00 Discussion
13.00-14.00 Lunch
   
  Abstract Session I (Aylin Yilmaz and Anders Sönnerborg)
14.00-14.20 Oral 1
Increasing prevalence of transmitted drug resistance mutations in patients diagnosed with HIV in Sweden 2010 – 2014 (Emmi Andersson, Sweden)
14.20-14.40 Oral 2
Molecular epidemiology of HIV-1 in Iceland (Malik Sallam, Sweden)
14.40-15.00 Oral 3
HIV-1 Transmission from MSM to heterosexuals and increasing proportions of circulating recombinant forms in the nordic countries (Joakim Esbjörnsson, Sweden)
15.00-15.20 Oral 4
Genome-wide population genomics of intrapatient HIV-1 evolution (Jan Albert, Sweden)
15.20-15.40 Coffee and exhibition/posters
   
  Plenary Session V – Antiviral treatment (Veronica Svedhem Johansson and Magnus Gottfredsson)
15.40-16.10 Plenary 11
Savings from switching to generic antiretrovirals (Andrew Hill, UK)
16.10-16.20 Discussion
16.20-16.50 Plenary 12
Global epidemiology of tenofovir resistance following failure of first line WHO recommended regimens (Ravindra Gupta, UK)
16.50-17.00 Discussion
17.00-17.20 Coffee and exhibition/posters
17.20-18.20 Satellite Symposium IV – Abbvie
Modern HCV treatment in HIV-positive individuals (Mark Nelson, UK)
18.20-18.30 Short break
18.30-19.30 Satellite Symposium V – Gilead
Fight against hepatitis C: National strategies, actions and treatments in Scotland and Spain (Maria Buti, Spain and David Goldberg, Scotland)
Moderator: Soo Aleman, Sweden
  Dinner
   

 

Friday October 2
08.00-09.00 Satellite Symposium VI – BMS
Real world data on treatment of chronic HCV patients – advanced disease and genotype 3 (Ola Weiland, Sweden)
   
  Plenary Session VI – Treatment as prevention (Ola Weiland and Nina Weis)
09.10-09.40 Plenary 13
Hepatitis C, treatment as prevention (Hannah Woodall, UK)
09.40-09.50 Discussion
09.50-10.20 Plenary 14
The road to a hepatitis C virus free world – the Georgian approach (Lali Sharvadze, Georgia)
10.20-10.30 Discussion
10.30-11.15 Coffee and Poster exhibition
   
  Abstract Session II (Magnus Gottfredsson and Matti Ristola)
11.15-11.35 Oral 5
Prevalence of HIV co-infection among newly diagnosed patients with chronic hepatitis B or C in Denmark – a nationwide cohort study (Sofie Hallager, Denmark)
11.35-11.55 Oral 6
A care model with good retention yielded to control of HIV outbreak among injecting drug users (IDU) in Helsinki area (Susan Simola, Finland)
12.00-12.10 HIV & Hepatitis Nordic Conference 2015 Abstract Award (Jan Gerstoft)
   
  Plenary Session VII – (Nina Weis and Ola Weiland)
12.10-12.40 Plenary 15
Optimal HCV regimen for cure (Johannes Vermehren, Germany)
12.40-12.50 Discussion
12.50-13.20 Plenary 16
Expanding HCV treatment to mild disease (Graham Foster, UK)
13.20-13.30 Discussion
   
13.30-14.30 Lunch
   
  Plenary Session VIII – (Leo Flamholc and Arild Maeland)
14.30-15.00 Plenary 17
What’s up for treatment of hepatitis B (Pietro Lampertico, Italy)
15.00-15.10 Discussion
15.10-15.40 Plenary 18
Risk for hepatocellular cancer in untreated and cured hepatitis C (Soo Aleman, Sweden)
15.40-15.50 Discussion
15.50-16.20 Plenary 19
Hepatitis C and HIV in resource limited countries (Anna Mia Ekström, Sweden)
16.20-16.30 Discussion
16.30-16.45 Concluding remarks (Anders Sönnerborg)
   

 

Program 2014

 

Thursday October 2
09.00-18.00 Registration is open between 09.00-18.00
11.00-12.00

Satellite Symposium I – Gilead
Global access challenges for HIV & HCV drugs
(moderator: Anna Mia Ekström, Sweden)

Global burden of HIV & HCV and treatment trends (Hans Rosling, Sweden)

An Overview of Gilead’s Access Program (Clifford Samuel, USA)
12.00-13.00 Lunch
   
  Opening session (Magnus Gisslén, Sweden and Johanna Brännström, Sweden)
13.00-13.15 Welcome (Magnus Gisslén, Sweden)
13.15-14.00 Opening Plenary 1 – Achieved results from the Danish HIV cohort (Niels Obel, Denmark)
14.00-14.15 Discussion
14.15-14.45 Coffee and exhibition/posters
   
  Plenary session I – Vaccine and immunotherapy. (Anders Sönnerborg, Sweden and Magnús Gottfreðsson, Iceland)
14.45-15.15 Plenary 2. Current status of HIV vaccine and immunotherapy research (Robin A Weiss, UK)
15.15-15.30 Discussion
  Plenary session II –Last year’s most important achievements in the HIV research field (Anders Sönnerborg, Sweden and Magnús Gottfreðsson, Iceland)
15.30-16.00 Plenary 3. Top 5 in clinical HIV research 2013/14 (Margaret Johnson, UK)
16.00-16.15 Discussion
16.15-16.45 Plenary 4. Top 5 in basic HIV research 2013/14 (Francesca Chiodi, Sweden)
16.45-17.00 Discussion
   
17.15-18.15

Satellite Symposium II – GSK/ViiV
Tailoring Therapy Today: Talking about Dolutegravir

Welcome and Introduction (Magnus Gisslén, Sweden)

Living with HIV – a patients perspective and unmet needs (Ophelia Haanyama, Sweden)

Dolutegravir – a new treatment option in HIV – clinical background (Anders Sönnerborg, Sweden)

HIV treatment and drug interactions – considerations for using Dolutegravir in clinical practice (David Back, UK)

Q&A-session and Summary (Magnus Gisslén, Sweden)
   
  Dinner
   

 

Friday October 3
07.30-18.00 Registration is open between 07.30-18.00
08.00-09.00
Breakfast will be served

Satellite Symposium III – Janssen
Welcome and Intruduction to MDR-Tb (Judith Bruchfeld, Sweden)

Development of bedaquiline: A Rocky Road (Koen Andries, Belgium)

Presentation of HIV speaker (Stefan Lindbäck, Sweden)

HIV treatment; current status and future perspectives (Hans-Jürgen Stellbrink, Germany)

Closing remarks (Judith Bruchfeld, Sweden)
   
  Abstract Session I (Anders Blaxhult, Sweden and Matti Ristola, Finland)
09.00-09.20 Oral 1 – The Occurrence of Transient Viral Blips during Suppressive Antiretroviral Treatment is Associated with High Baseline HIV-1 RNA Levels (Erik Sörstedt, Sweden)
09.20-09.40 Oral 2 – High incidence of high grade cervical neoplasia among women with HIV in Sweden (Christina Carlander, Sweden)
09.40-10.00 Oral 3 – Mild neurocognitive impairment is associated with CNS immunoactivation and neuronal injury in HIV-infected patients on effective antiviral therapy (Arvid Edén, Sweden)
   
10.00-11.00 Coffee and Poster exhibition
   
  Plenary Session III – Cure and immune activation (Magnús Gottfreðsson, Iceland and Leo Flamholc, Sweden)
11.00-11.30 Plenary 5. Current status of HIV cure research (David Margolis, USA)
11.30-11.40 Discussion
11.40-12.10 Plenary 6. The impact of persistent chronic immune activation in treated HIV (Peter Hunt, USA)
12.10-12.20 Discussion
   
12.20-13.30 Lunch
   
  Plenary Session IV – Antiviral treatment (Matti Ristola, Finland and Magnus Gisslén, Sweden)
13.30-14.00 Plenary 7. ART: How to balance the role of adverse events, efficacy, convenience, economy and risk of resistance (Graeme Moyle, UK)
14.00-14.15 Discussion
14.15-14.45 Plenary 8. New era of hepatitis C treatment in HIV/HCV co-infection (Stefan Zeuzem, Germany)
14.45-15.00 Discussion
15.00-15.30 Plenary 9. Alternative ART regimens for patients ineligible for nucs (José Gatell, Spain)
15.30-15.45 Discussion
15.45-16.15 Coffee and Poster exhibition
   
  Plenary Session V (Anders Sönnerborg, Sweden and Aylin Yilmaz, Sweden)
16.15-16.45 Plenary 10. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective (Christophe Fraser, UK)
16.45-17.00 Discussion
17.00-17.30 Plenary 11. Phylogeographic analysis of the global HIV epidemic (Dimitros Paraskevis, Greece)
17.30-17.45 Discussion
   
17.45-18.00 HIV Nordic 2014 Abstract Award (Lars Moberg, Sweden)
   
18.00-18.15 Concluding remarks (Anders Sönnerborg, Sweden)